Windtree Therapeutics, Inc.
Records under this name other than the patents Windtree Therapeutics, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 13 patents it holds.
Back to Windtree Therapeutics, Inc.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,197,869 | Istaroxime-Containing Intravenous Formulation for the Treatment of Acute Heart Failure (AHF) now held by Seismic Pharmaceuticals Operations LLC In force · Medium confidence | In force | Medium confidence | |
| US 11,583,540 | Istaroxime-Containing Intravenous Formulation for the Treatment of Acute Heart Failure (AHF) now held by Seismic Pharmaceuticals Operations LLC In force · Low confidence | In force | Low confidence | |
| US 12,343,350 | Istaroxime-Containing Intravenous Formulation for the Treatment of Acute Heart Failure (AHF) now held by Seismic Pharmaceuticals Operations LLC In force · Medium confidence | In force | Medium confidence | |
| US 12,503,484 | Androstane Derivatives with Activity as Pure or Predominantly Pure Stimulators of SERCA2a for the Treatment of Heart Failure. now held by Seismic Pharmaceuticals Operations LLC In force · High confidence | In force | High confidence | |
| US 7,541,331 | Surfactant Treatment Regimen Term ended Term ended Jan 6, 2026 · High confidence | Term ended | Term ended Jan 6, 2026 | High confidence |
| US 7,582,312 | Methods to Produce Lung Surfactant Formulations via Lyophilization and Formulations and Uses Thereof Lapsed on the fee record Ended Sep 1, 2017 · High confidence | Lapsed on the fee record | Ended Sep 1, 2017 | High confidence |
| US 8,337,815 | Pulmonary Surfactant Formulations Lapsed on the fee record Ended Dec 25, 2016 · High confidence | Lapsed on the fee record | Ended Dec 25, 2016 | High confidence |
| 17/598,719 | Inhibitors of Atypical Protein Kinase C and Their Use in Treating Hedgehog Pathway-Dependent Cancers Abandoned Abandoned Apr 28, 2026 | Abandoned | Abandoned Apr 28, 2026 | |
| 18/858,086 | Istaroxime-Containing Intravenous Formulation for the Treatment of Pre-Cardiogenic Shock and Cardiogenic Shock Pending Term is not computable until grant, so no date is shown and no estimate is implied. | Pending | Term is not computable until grant, so no date is shown and no estimate is implied. | |
| 19/139,166 | Solid Forms of {5-Cyclopropyl-2-[2-(3,6-difluoro¬pyridin-2-ylamino)-pyridin-4-yl]-pyrido[3,4-d]pyrimidin-4-yl }-( (S)-3,3-Dimethyl-PIPERIDIN-4-YL)-AMINE now held by Cancer Research Technology Limited Pending Term is not computable until grant, so no date is shown and no estimate is implied. | Pending | Term is not computable until grant, so no date is shown and no estimate is implied. |